DelveInsight’s, “Diffuse Large B-Cell Lymphoma Pipeline Insight 2024” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Diffuse Large B-Cell Lymphoma pipeline landscape. It covers the Diffuse Large B-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Diffuse Large B-Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Diffuse Large B-Cell Lymphoma Research. Learn more about our innovative pipeline today! @ Diffuse Large B-Cell Lymphoma Pipeline Outlook
Key Takeaways from the Diffuse Large B-Cell Lymphoma Pipeline Report
- In November 2024:- Genmab- The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.
- In November 2024:- Pfizer- The purpose of this study is to learn about the effects of two study medicines (maplirpacept [PF-07901801] and glofitamab) when given together for the treatment of diffuse large B-cell lymphoma (DLBCL) that is relapsed or is refractory. Relapsed means has returned after last treatment. Refractory means that it has not responded to last treatment. The two study medicines are given after a single dose of obinutuzumab which is the third study medicine.
- DelveInsight’s Diffuse Large B-Cell Lymphoma pipeline report depicts a robust space with 70+ active players working to develop 75+ pipeline therapies for Metastatic Prostate Cancer treatment.
- The leading Diffuse Large B-Cell Lymphoma Companies such as Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutics, Otsuka Pharmaceutical, OncoNano Medicine Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others.
- Promising Diffuse Large B-Cell Lymphoma Therapies such as R-miniCHOP + Acalabrutinib, Selinexor, Tafasitamab, Lenalidomide, and others.
Stay informed about the cutting-edge advancements in Diffuse Large B-Cell Lymphoma treatments. Download for updates and be a part of the revolution in cancer care @ Diffuse Large B-Cell Lymphoma Clinical Trials Assessment
Diffuse Large B-Cell Lymphoma Emerging Drugs Profile
- Brentuximab vedotin: Pfizer
Brentuximab vedotin (Adcetris) is an anti-neoplastic agent. It is indicated for the treatment of patients with Classical Hodgkin lymphoma (HL) after failure of autologous hematopoietic stem cell transplantation (auto-HSCT) or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates. Adcetris is also indicated for the treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant (ASCT), also indicated for the treatment of adult patients with relapsed or refractory systemic anaplastic large cell lymphoma, for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) and CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, for the treatment of adult patients with relapsed or refractory CD30+ cutaneous T- cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adcetris is indicated for the first-line pediatric treatment for CD30-positive Hodgkin lymphoma. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
- THOR-707: Sanofi
THOR-707 is a precisely PEGylated version of IL-2, where the PEG chain is attached to a novel amino acid inserted at a location on IL-2 that prevents it from engaging the alpha-receptor and binding to immune receptors that cause drug toxicities (IL-2R-alpha, CD25). The engineered IL-2 retains near-native binding to the beta-gamma receptors that selectively expand tumor-killing T effector cells and Natural Killer (NK) cells without the alpha-mediated immunosuppressive effects of regulatory T cells or eosinophil-mediated vascular leak syndrome. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
- Abexinostat: Xynomic Pharmaceuticals
Abexinostat (Xynomic Pharmaceuticals) is a broad histone deacetylase (HDAC) inhibitor. HDAC enzymes (also known as lysine deacetylase) cleave acetyl groups from N-acetyl lysine amino acids on a histone. HDAC inhibition leads to highly acetylated histones and chromatin reshaping. In addition to altering histone acetylation, HDAC inhibitors can also influence the degree of acetylation on non-histone proteins, increasing or repressing their activity. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Diffuse Large B-cell lymphoma.
- RNK05047: Ranok Therapeutics
RNK05047 is a first-in-class, small-molecule, tumor- and BRD4-selective protein degrader that was discovered and developed using Ranok’s proprietary approach to targeted protein degradation, CHAMPTM. The bromodomain transcription factor BRD4 is a key regulator of oncogenes such as MYC and BCL2 and is involved in diverse cancer types. CHAMP-1 is a Phase I/II trial of RNK05047 currently underway in the US that will assess its safety, tolerability, and pharmacokinetics, and also includes measures of anti-tumor activity and pharmacodynamics readouts as secondary endpoints.
- BMF-219: Biomea Fusion
BMF-219 is an oral investigational covalent menin inhibitor. Data suggests that optimized covalent inhibitors can provide deeper inhibition while being better tolerated than some conventional reversible inhibitors. BMF-219 is being developed for genetically defined AML, ALL, DLBCL, MM and CLL patients. BMF-219 blocks the interaction of menin and MLL (AML, ALL), and limits the activity and/or expression of NPM1, MYC, HOX, and MEIS1, all known drivers of oncogenic proliferation and survival. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
- ADI-001: Adicet Bio
ADI-001 is an investigational allogeneic gamma delta CAR T cell therapy being developed as a potential treatment for relapsed or refractory B-cell NHL. ADI-001 targets malignant B-cells via an anti-CD20 CAR and via the gamma delta innate and T cell endogenous cytotoxicity receptors. Gamma delta T cells engineered with an anti-CD20 CAR have demonstrated potent anti-tumor activity in preclinical models, leading to long-term control of tumor growth. In April 2022, ADI-001 was granted Fast Track Designation by the FDA for the potential treatment of relapsed or refractory B-cell NHL. Currently, the drug is in Phase I stage of its clinical trial for the treatment of Diffuse Large B Cell Lymphoma.
Learn more about Diffuse Large B-Cell Lymphoma Drugs Opportunities in our groundbreaking Diffuse Large B-Cell Lymphoma research and development projects @ Diffuse Large B-Cell Lymphoma Unmet Needs
Diffuse Large B-cell Lymphoma Companies
Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutics, Otsuka Pharmaceutical, OncoNano Medicine Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others.
Diffuse Large B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
Diffuse Large B-Cell Lymphoma Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Discover the latest advancements in Diffuse Large B-Cell Lymphoma treatment by visiting our website. Stay informed about how we’re transforming the future of oncology @ Diffuse Large B-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives
Scope of the Diffuse Large B-Cell Lymphoma Pipeline Report
- Coverage- Global
- Diffuse Large B-Cell Lymphoma Companies- Miltenyi Biomedicine, Adicet Bio, VelosBio, Novartis Pharmaceuticals, Sanofi, Eisai Co, Schrodinger, Sana Biotechnology, Ranok Therapeutics, Monte Rosa Therapeutics, Otsuka Pharmaceutical, OncoNano Medicine Regeneron Pharmaceuticals, Hoffmann-La Roche, Celgene, Nurix Therapeutics, NovalGen, Nektar Therapeutics, Genentech, CSPC ZhongQi Pharmaceutical Technology, and others.
- Diffuse Large B-Cell Lymphoma Therapies- R-miniCHOP + Acalabrutinib, Selinexor, Tafasitamab, Lenalidomide, and others.
- Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Diffuse Large B-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Diffuse Large B-Cell Lymphoma pipeline on our website @ Diffuse Large B-Cell Lymphoma Emerging Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Diffuse Large B-Cell Lymphoma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Diffuse Large B-Cell Lymphoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Brentuximab vedotin: Pfizer
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- THOR-707: Sanofi
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- ADI-001: Adicet Bio
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Diffuse Large B-Cell Lymphoma Key Companies
- Diffuse Large B-Cell Lymphoma Key Products
- Diffuse Large B-Cell Lymphoma- Unmet Needs
- Diffuse Large B-Cell Lymphoma- Market Drivers and Barriers
- Diffuse Large B-Cell Lymphoma- Future Perspectives and Conclusion
- Diffuse Large B-Cell Lymphoma Analyst Views
- Diffuse Large B-Cell Lymphoma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Diffuse Large B-cell Lymphoma Pipeline Drugs Report 2024 (Updated) | DelveInsight